



AMERICAN ACADEMY™
OF OPHTHALMOLOGY

5

Neuro-Ophthalmology

2017–2018
BCSC
Basic and Clinical
Science Course™

The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Academy of Ophthalmology designates this enduring material for a maximum of 15 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME expiration date: June 1, 2020. *AMA PRA Category 1 Credits*[™] may be claimed only once between June 1, 2017, and the expiration date.

BCSC[®] volumes are designed to increase the physician's ophthalmic knowledge through study and review. Users of this activity are encouraged to read the text and then answer the study questions provided at the back of the book.

To claim *AMA PRA Category 1 Credits*[™] upon completion of this activity, learners must demonstrate appropriate knowledge and participation in the activity by taking the posttest for Section 5 and achieving a score of 80% or higher. For further details, please see the instructions for requesting CME credit at the back of the book.

The Academy provides this material for educational purposes only. It is not intended to represent the only or best method or procedure in every case, nor to replace a physician's own judgment or give specific advice for case management. Including all indications, contraindications, side effects, and alternative agents for each drug or treatment is beyond the scope of this material. All information and recommendations should be verified, prior to use, with current information included in the manufacturers' package inserts or other independent sources, and considered in light of the patient's condition and history. Reference to certain drugs, instruments, and other products in this course is made for illustrative purposes only and is not intended to constitute an endorsement of such. Some material may include information on applications that are not considered community standard, that reflect indications not included in approved FDA labeling, or that are approved for use only in restricted research settings. **The FDA has stated that it is the responsibility of the physician to determine the FDA status of each drug or device he or she wishes to use, and to use them with appropriate, informed patient consent in compliance with applicable law.** The Academy specifically disclaims any and all liability for injury or other damages of any kind, from negligence or otherwise, for any and all claims that may arise from the use of any recommendations or other information contained herein.

AAO, AAOE, American Academy of Ophthalmology, Basic and Clinical Science Course, BCSC, EyeCare America, EyeNet, EyeSmart, EyeWiki, Focal Points, IRIS, ISRS, OKAP, ONE, Ophthalmic Technology Assessments, *Ophthalmology*, Preferred Practice Pattern, ProVision, SmartSight, The Ophthalmic News & Education Network, and the AAO logo (shown on cover) and tagline (Protecting Sight. Empowering Lives.) are, among other marks, the registered trademarks and trademarks of the American Academy of Ophthalmology.

Cover image: Fundus photograph showing an arteriovenous malformation (racemose angioma) of the retina in a patient with Wyburn-Mason syndrome. (*Courtesy of Mark J. Greenwald, MD.*)

Copyright © 2017 American Academy of Ophthalmology. All rights reserved.
No part of this publication may be reproduced without written permission.

Printed in the United States of America.

Basic and Clinical Science Course

Louis B. Cantor, MD, Indianapolis, Indiana, *Senior Secretary for Clinical Education*

Christopher J. Rapuano, MD, Philadelphia, Pennsylvania, *Secretary for Lifelong Learning and Assessment*

George A. Cioffi, MD, New York, New York, *BCSC Course Chair*

Section 5

Faculty

M. Tariq Bhatti, MD, *Chair*, Durham, North Carolina

Valerie Biousse, MD, Atlanta, Georgia

Swaraj Bose, MD, Los Angeles, California

Julie Falardeau, MD, Portland, Oregon

Leonard A. Levin, MD, PhD, Montreal, Canada

Paul H. Phillips, MD, Little Rock, Arkansas

Zöe R. Williams, MD, Rochester, New York

Helen V. Danesh-Meyer, MBCHB, MD, *Consultant*, Auckland, New Zealand

The Academy wishes to acknowledge the *North American Neuro-Ophthalmology Society (NANOS)* for recommending faculty members to the BCSC Section 5 committee.

The Academy also wishes to acknowledge the following committees for review of this edition:

Committee on Aging: Fiona Costello, MD, Calgary, Canada

Vision Rehabilitation Committee: William M. McLaughlin Jr, DO, Allentown, Pennsylvania

Practicing Ophthalmologists Advisory Committee for Education: Steven J. Grosser, MD, *Primary Reviewer*, Golden Valley, Minnesota; Edward K. Isbey III, *Chair*, Asheville, North Carolina; Alice Bashinsky, MD, Asheville, North Carolina; David Browning, MD, PhD, Charlotte, North Carolina; Bradley D. Fouraker, MD, Tampa, Florida; Stephen R. Klapper, MD, Carmel, Indiana; James A. Savage, MD, Memphis, Tennessee; Michelle S. Ying, MD, Ladson, South Carolina



European Board of Ophthalmology: Klara Landau, MD, FEBO, *EBO Chair*, Zürich, Switzerland; Marko Hawlina, MD, PhD, *EBO Liaison*, Ljubljana, Slovenia; François-Xavier Borruat, MD, Lausanne, Switzerland; Antonella Boschi, MD, Brussels, Belgium; Michael

Anthony Burdon, MBBS, Birmingham, England, United Kingdom; Wolf A. Lagrèze, MD, Freiburg, Germany; Dan Milea, MD, PhD, Angers, France

Financial Disclosures

Academy staff members who contributed to the development of this product state that within the 12 months prior to their contributions to this CME activity and for the duration of development, they have had no financial interest in or other relationship with any entity discussed in this course that produces, markets, resells, or distributes ophthalmic health care goods or services consumed by or used in patients, or with any competing commercial product or service.

The authors and reviewers state that within the 12 months prior to their contributions to this CME activity and for the duration of development, they have had the following financial relationships:*

Dr Bhatti: Alexion (C), Novartis Pharmaceuticals (C, L), Receptos (C)

Dr Biousse: GenSight Biologics (C)

Dr Browning: Aerpio Therapeutics (S), Alcon (S), Alimera Sciences (C), Genentech (S), Novartis Pharmaceuticals (S), Ohr Pharmaceutical (S), Pfizer (S), Regeneron Pharmaceuticals (S)

Dr Danesh-Meyer: Allergan (S)

Dr Fouraker: Addition Technology (C, L), Alcon (C, L), KeraVision (C, L), OASIS Medical (C, L)

Dr Grosser: Ivantis (O)

Dr Isbey: Alcon (S), Allscripts (C), Bausch + Lomb (S), Medflow (C), Oculis Clinical Research (S)

Dr Landau: Santhera Pharmaceuticals (C)

Dr Levin: Aerie Pharmaceuticals (C), Allergan (C), Inotek Pharmaceuticals (C), Merz (C), Quark Pharmaceuticals (C), Regenera Pharma (C), Synta Pharmaceuticals (C), Teva Pharmaceutical Industries (C)

Dr Milea: Alcon (L)

Dr Savage: Allergan (L)

The other authors and reviewers state that within the past 12 months prior to their contributions to this CME activity and for the duration of development, they have had no financial interest in or other relationship with any entity discussed in this course that produces, markets, resells, or distributes ophthalmic health care goods or services consumed by or used in patients, or with any competing commercial product or service.

*C = consultant fees, paid advisory boards, or fees for attending a meeting; L = lecture fees (honoraria), travel fees, or reimbursements when speaking at the invitation of a commercial sponsor; O = equity ownership/stock options of publicly or privately traded firms (excluding mutual funds) with manufacturers of commercial ophthalmic products or commercial ophthalmic services; P = patents and/or royalties that might be viewed as creating a potential conflict of interest; S = grant support for the past year (all sources) and all sources used for a specific talk or manuscript with no time limitation

Recent Past Faculty

Rod Foroozan, MD
Lynn K. Gordon, MD, PhD
Aki Kawasaki, MD
Michael S. Lee, MD
Prem S. Subramanian, MD, PhD

In addition, the Academy gratefully acknowledges the contributions of numerous past faculty and advisory committee members who have played an important role in the development of previous editions of the Basic and Clinical Science Course.

American Academy of Ophthalmology Staff

Dale E. Fajardo, *Vice President, Education*
Beth Wilson, *Director, Continuing Professional Development*
Ann McGuire, *Acquisitions and Development Manager*
Stephanie Tanaka, *Publications Manager*
D. Jean Ray, *Production Manager*
Kimberly Torgerson, *Publications Editor*
Beth Collins, *Medical Editor*
Naomi Ruiz, *Publications Specialist*

American Academy of Ophthalmology
655 Beach Street
Box 7424
San Francisco, CA 94120-7424

Contents

General Introduction	xv
Objectives	1
Introduction	3
1 Neuro-Ophthalmic Anatomy	5
Bony Anatomy	5
Skull Base	5
The Orbit	6
Vascular Anatomy	11
Arterial System	11
Venous System	21
Afferent Visual Pathways	23
Retina	23
Optic Nerve	26
Optic Chiasm	27
Optic Tract	28
Cortex	29
Efferent Visual System (Ocular Motor Pathways)	31
Cortical Input	32
Subcortical Structures	33
Brainstem	34
Ocular Motor Cranial Nerves	40
Extraocular Muscles	45
Sensory and Facial Motor Anatomy	47
Trigeminal Nerve (Fifth Cranial Nerve)	47
Facial Nerve (Seventh Cranial Nerve)	49
Eyelids	52
Ocular Autonomic Pathways	52
Sympathetic Pathways	52
Parasympathetic Pathways	54
2 Neuroimaging in Neuro-Ophthalmology	57
Introduction	57
Computed Tomography	60
Magnetic Resonance Imaging	60
Vascular Imaging	67
Catheter Angiography	68
Magnetic Resonance Angiography and Magnetic Resonance Venography	68

Computed Tomography Angiography and Computed Tomography Venography	69
Metabolic and Functional Imaging Modalities	70
Ultrasonography	70
Crucial Questions in Imaging	71
When to Order	71
What to Order	71
How to Order	73
Negative Study Results	73
Glossary of Select Neuroimaging Terminology	75
3 The Patient With Decreased Vision: Evaluation	77
History	77
Unilateral Versus Bilateral Involvement	77
Time Course of Vision Loss	77
Associated Symptoms	78
Examination	78
Visual Acuity Testing	78
Color Vision Testing	78
Pupillary Testing	79
Fundus Examination	81
Visual Field Evaluation	83
Adjunct Testing	88
4 The Patient With Decreased Vision: Classification and Management	99
Ocular Media Abnormality	99
Retinopathy	99
Acute Idiopathic Blind-Spot Enlargement, Acute Zonal Occult Outer Retinopathy, and Multiple Evanescent White Dot Syndrome	100
Cone Dystrophy	102
Autoimmune Retinopathies and Paraneoplastic Retinopathies	102
Optic Neuropathy	103
Visual Field Patterns in Optic Neuropathy	103
Causes of Optic Neuropathy	104
Optic Atrophy	145
Chiasmal Lesions	146
Visual Field Loss Patterns	146
Etiology of Chiasmal Disorders	147
Retrochiasmal Lesions	152
Optic Tract	153
Lateral Geniculate Body	154
Temporal Lobe	155
Parietal Lobe	156
Occipital Lobe	156
Vision Rehabilitation	159

5	The Patient With Transient Visual Loss	161
	Examination	163
	Transient Monocular Visual Loss	163
	Ocular Causes	163
	Orbital Causes	164
	Vascular Causes	164
	Binocular Transient Visual Loss	171
	Migraine.	171
	Occipital Mass Lesions.	172
	Occipital Ischemia	172
	Occipital Seizures	172
6	The Patient With Illusions, Hallucinations, and Disorders of Higher Cortical Function	173
	The Patient With Visual Illusions and Distortions	173
	Ocular Origin	174
	Optic Nerve Origin	175
	Cortical Origin	175
	The Patient With Hallucinations	175
	Ocular Origin	175
	Optic Nerve Origin	176
	Cortical Origin	176
	The Patient With Disorders of Higher Cortical Function	178
	Disorders of Recognition	179
	Disorders of Visual-Spatial Relationships	180
	Disorders of Awareness of Vision or Visual Deficit	180
7	The Patient With Abnormal Ocular Motility or Diplopia.	183
	History	183
	Physical Examination	184
	Monocular Diplopia	185
	Differentiating Paretic From Restrictive Etiologies of Diplopia	186
	Comitant and Incomitant Deviations	186
	Localization	187
	Supranuclear Causes of Abnormal Ocular Motility	188
	Nuclear Causes of Diplopia	188
	Internuclear Causes of Diplopia	189
	Internuclear Ophthalmoplegia	189
	One-and-a-Half Syndrome	191
	Infranuclear Causes of Diplopia	191
	Third Cranial Nerve Palsy	193
	Fourth Cranial Nerve Palsy	198
	Sixth Cranial Nerve Palsy	200
	Ocular Neuromyotonia	202
	Paresis of More Than One Cranial Nerve	202

Cavernous Sinus and Superior Orbital Fissure Involvement	202
Neuromuscular Junction Causes of Diplopia	206
Myopathic, Restrictive, Orbital, and Other Causes of Diplopia	206
Thyroid Eye Disease	206
Posttraumatic Restriction	206
Postsurgical Restriction	207
Orbital Myositis	207
Chronic Progressive External Ophthalmoplegia	208
Neoplastic Involvement	208
Brown Syndrome	208
Heavy Eye Syndrome	208
Sagging Eye Syndrome	209
Refractive Procedure–Induced Diplopia	209
Foveal Displacement Syndrome	209

8 The Patient With Supranuclear Disorders of Ocular Motility 211

Fundamental Principles of Ocular Motor Control	212
Supranuclear Ocular Motor Systems: Function, Anatomy, Clinical Testing, and Disorders of Eye Movements	213
Ocular Fixation System	213
Vestibular-Ocular System (Vestibular-Ocular Reflex)	214
Optokinetic System (Optokinetic Nystagmus)	218
Saccadic System	219
Smooth-Pursuit System	224
Vergence System	226
Gaze Preference, Gaze Palsy, and Tonic Deviations	228

9 The Patient With Nystagmus or Spontaneous Eye Movement Disorders 233

Introduction	233
Early-Onset (Childhood) Nystagmus	235
Infantile Nystagmus Syndrome (Congenital Nystagmus)	235
Fusional Maldevelopment Nystagmus Syndrome (Latent Nystagmus)	237
Heimann-Bielschowsky Phenomenon	238
Spasmus Nutans Syndrome	239
Gaze-Evoked Nystagmus	240
Rebound Nystagmus	240
Vestibular Nystagmus	241
Peripheral Vestibular Nystagmus	241
Central Forms of Vestibular Nystagmus	243
Acquired Pendular Nystagmus	246
Oculopalatal Myoclonus or Tremor	246
See-Saw Nystagmus	247
Dissociated Nystagmus With Internuclear Ophthalmoplegia	247

Saccadic Intrusions	247
Saccadic Intrusions With Normal Intersaccadic Intervals	247
Saccadic Intrusions Without Normal Intersaccadic Intervals	248
Voluntary Flutter (Voluntary “Nystagmus”)	249
Additional Eye Movement Disorders	250
Convergence-Retraction Nystagmus	250
Superior Oblique Myokymia	250
Oculomasticatory Myorhythmia	251
10 The Patient With Pupillary Abnormalities	253
History	253
Pupillary Examination	253
Baseline Pupil Size	254
Pupil Irregularity	255
Anisocoria	255
Normal Pupillary Response to Light	255
Anisocoria Equal in Dim and Bright Light	257
Anisocoria Greater in Dim Light	257
Anisocoria Greater in Bright Light	262
Disorders of Pupillary Reactivity: Light–Near Dissociation	266
Afferent Visual Pathway	266
Midbrain	266
Aberrant Regeneration	267
Other Pupillary Disorders	267
Benign Episodic Unilateral Mydriasis	267
11 The Patient With Eyelid or Facial Abnormalities	269
Examination Techniques	269
Ptosis	272
Congenital Ptosis	272
Acquired Ptosis	273
Pseudoptosis	274
Apraxia of Eyelid Opening	274
Eyelid Retraction	274
Abnormalities of Facial Movement	275
Seventh Cranial Nerve Disorders	277
Disorders of Underactivity of the Seventh Cranial Nerve	277
Disorders of Overactivity of the Seventh Cranial Nerve	281
12 The Patient With Head, Ocular, or Facial Pain	287
Head Pain	287
Migraine and Tension-type Headache	288
Trigeminal Autonomic Cephalgias and Hemicrania Continua	293
Idiopathic Stabbing Headache	294
Inherited Encephalopathies Resembling Migraine	294
Ocular and Orbital Pain	295
Trochlear Headache and Trochleitis	296
Photophobia	296

Facial Pain	296
Trigeminal Neuralgia	297
Occipital Neuralgia	297
Temporomandibular Disease	297
Internal Carotid Artery Dissection	297
Herpes Zoster Ophthalmicus	298
Neoplastic Processes	298

13 The Patient With Nonorganic Ophthalmic

Disorders	299
Clinical Profile	300
Examination Techniques	301
Afferent Visual Pathway	301
Ocular Motility and Alignment	309
Pupils and Accommodation	310
Eyelid Position and Function	310
Management of the Patient With Nonorganic Ophthalmic Disorders	311

14 Selected Systemic Conditions With

Neuro-Ophthalmic Signs	313
Immunologic Disorders	313
Giant Cell Arteritis	313
Multiple Sclerosis	315
Neuromyelitis Optica	320
Myasthenia Gravis	323
Thyroid Eye Disease	326
Sarcoidosis	327
Inherited Disorders With Neuro-Ophthalmic Signs	328
Myopathies	328
Neurocutaneous Syndromes	330
Selected Neuro-Ophthalmic Disorders Associated With Pregnancy	333
Posterior Reversible Encephalopathy Syndrome	333
Lymphocytic Hypophysitis	335
Cerebrovascular Disorders	335
Transient Visual Loss	336
Vertebrobasilar System Disease	336
Cerebral Aneurysms	338
Arterial Dissection	342
Arteriovenous Malformations	343
Cerebral Venous Thrombosis	345
Reversible Cerebral Vasoconstriction Syndrome	346
Neuro-Ophthalmic Manifestations of Infectious Diseases	348
Human Immunodeficiency Virus Infection	348
Herpesvirus	350
Mycobacterium	350

Syphilis	351
Progressive Multifocal Leukoencephalopathy	351
Toxoplasmosis	352
Lyme Disease	352
Fungal Infections	353
Prion Diseases	357
Radiation Therapy	357
Basic Texts	359
Related Academy Materials	361
Requesting Continuing Medical Education Credit	363
Study Questions	365
Answer Sheet for Section 5 Study Questions	373
Answers	375
Index	381

General Introduction

The Basic and Clinical Science Course (BCSC) is designed to meet the needs of residents and practitioners for a comprehensive yet concise curriculum of the field of ophthalmology. The BCSC has developed from its original brief outline format, which relied heavily on outside readings, to a more convenient and educationally useful self-contained text. The Academy updates and revises the course annually, with the goals of integrating the basic science and clinical practice of ophthalmology and of keeping ophthalmologists current with new developments in the various subspecialties.

The BCSC incorporates the effort and expertise of more than 90 ophthalmologists, organized into 13 Section faculties, working with Academy editorial staff. In addition, the course continues to benefit from many lasting contributions made by the faculties of previous editions. Members of the Academy Practicing Ophthalmologists Advisory Committee for Education, Committee on Aging, and Vision Rehabilitation Committee review every volume before major revisions. Members of the European Board of Ophthalmology, organized into Section faculties, also review each volume before major revisions, focusing primarily on differences between American and European ophthalmology practice.

Organization of the Course

The Basic and Clinical Science Course comprises 13 volumes, incorporating fundamental ophthalmic knowledge, subspecialty areas, and special topics:

- 1 Update on General Medicine
- 2 Fundamentals and Principles of Ophthalmology
- 3 Clinical Optics
- 4 Ophthalmic Pathology and Intraocular Tumors
- 5 Neuro-Ophthalmology
- 6 Pediatric Ophthalmology and Strabismus
- 7 Orbit, Eyelids, and Lacrimal System
- 8 External Disease and Cornea
- 9 Intraocular Inflammation and Uveitis
- 10 Glaucoma
- 11 Lens and Cataract
- 12 Retina and Vitreous
- 13 Refractive Surgery

In addition, a comprehensive Master Index allows the reader to easily locate subjects throughout the entire series.

References

Readers who wish to explore specific topics in greater detail may consult the references cited within each chapter and listed in the Basic Texts section at the back of the book.

These references are intended to be selective rather than exhaustive, chosen by the BCSC faculty as being important, current, and readily available to residents and practitioners.

Videos

This edition of Section 5, *Neuro-Ophthalmology*, includes videos related to topics covered in the book. The videos were selected by members of the BCSC faculty and are available to readers of the print and electronic versions of Section 5. Mobile-device users can scan the QR code below (a QR-code reader must already be installed on the device) to access the video content.

Study Questions and CME Credit

Each volume of the BCSC is designed as an independent study activity for ophthalmology residents and practitioners. The learning objectives for this volume are given on page 1. The text, illustrations, and references provide the information necessary to achieve the objectives; the study questions allow readers to test their understanding of the material and their mastery of the objectives. Physicians who wish to claim CME credit for this educational activity may do so by following the instructions given at the end of the book.

Conclusion

The Basic and Clinical Science Course has expanded greatly over the years, with the addition of much new text, numerous illustrations, and video content. Recent editions have sought to place greater emphasis on clinical applicability while maintaining a solid foundation in basic science. As with any educational program, it reflects the experience of its authors. As its faculties change and medicine progresses, new viewpoints emerge on controversial subjects and techniques. Not all alternate approaches can be included in this series; as with any educational endeavor, the learner should seek additional sources, including Academy Preferred Practice Pattern Guidelines.

The BCSC faculty and staff continually strive to improve the educational usefulness of the course; you, the reader, can contribute to this ongoing process. If you have any suggestions or questions about the series, please do not hesitate to contact the faculty or the editors.

The authors, editors, and reviewers hope that your study of the BCSC will be of lasting value and that each Section will serve as a practical resource for quality patient care.